General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Innovation at Novartis

Growing need for innovation in healthcare

Rapid aging of the population, greater access to healthcare in emerging markets and advances in science create opportunities to enhance the lives of patients through innovation.

Healthcare innovation generally refers to the drug discovery and development process – the translation of fundamental science into new drugs, vaccines, devices and diagnostic tests. This type of innovation requires significant investment and teams commanding specialized, yet complementary, skills.

Innovation at Novartis

Our strategy of focused diversification helps us to capitalize on this changing healthcare environment while balancing risk. Novartis has leading businesses in science-based, fast growing segments of healthcare.

Novartis aims to change the practice of medicine, and innovation at Novartis not only means developing effective, targeted medicines quickly, but also ensuring that these medicines get to the patients who need them.

Novartis strives to ensure that patients can benefit from new and effective drugs as quickly as possible by:

  • Prioritizing our research efforts based on sound science and patient need
  • Leveraging our core research and development capabilities across all divisions to continue building our pipeline of innovative pharmaceuticals; eye care treatments; affordable, high-quality generics; consumer health products; and vaccines and diagnostics
  • Shifting to a more integrated approach, working together with physicians and our customers to optimize patient outcomes
  • Identifying biomarkers to develop high-quality companion diagnostics in support of our medicines across all therapeutic areas
  • Carefully designing clinical trials to generate data that helps governments measure the economic benefits of new medicines
  • Collaborating with governments globally to create innovative pricing arrangements
  • Investing in forward-looking digital technologies that improve patient outcomes

The success of this strategy is evident in our long-established track record of research productivity. During the last four years, Novartis has received more approvals in the US and EU for new molecular entities than our competitors.